Advanced

Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.

Jenkins, Christine R ; Postma, Dirkje S ; Anzueto, Antonio R ; Make, Barry J ; Peterson, Stefan ; Eriksson, Göran LU and Calverley, Peter M (2015) In BMC Pulmonary Medicine 15.
Abstract
Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting β2-agonist (SABA) reliever use would predict short- and long-term exacerbation risk in COPD patients.
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
BMC Pulmonary Medicine
volume
15
article number
97
publisher
BioMed Central (BMC)
external identifiers
  • wos:000360042500001
  • pmid:26293575
  • scopus:84939503569
  • pmid:26293575
ISSN
1471-2466
DOI
10.1186/s12890-015-0077-0
language
English
LU publication?
yes
id
cc475f88-008a-4255-8816-24512ff8ab29 (old id 7840437)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26293575?dopt=Abstract
date added to LUP
2016-04-01 13:01:56
date last changed
2020-06-17 02:04:23
@article{cc475f88-008a-4255-8816-24512ff8ab29,
  abstract     = {Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting β2-agonist (SABA) reliever use would predict short- and long-term exacerbation risk in COPD patients.},
  author       = {Jenkins, Christine R and Postma, Dirkje S and Anzueto, Antonio R and Make, Barry J and Peterson, Stefan and Eriksson, Göran and Calverley, Peter M},
  issn         = {1471-2466},
  language     = {eng},
  publisher    = {BioMed Central (BMC)},
  series       = {BMC Pulmonary Medicine},
  title        = {Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.},
  url          = {https://lup.lub.lu.se/search/ws/files/3117439/8603246},
  doi          = {10.1186/s12890-015-0077-0},
  volume       = {15},
  year         = {2015},
}